Bree Shi

Bree Shi

Auto-generated profile, based on publicly available information

Bree Shi

Kidney Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
BSBree Shi
Bree Shi
TYTracey Ying
Tracey Ying
SCSteve J Chadban
Steve J Chadban
Kidney transplantation offers improved survival and quality of life compared to dialysis for most recipients; however, benefits for elderly patients (>70 years) remain uncertain. Using the Australia and New Zealand Dialysis and Transplant Registry (2009-2019), elderly transplant recipients were matched to a waitlisted dialysis patient by age, cause of end-stage kidney disease, and dialysis duration (paired controls). We censored dialysis patients at the time of transplant. Survival was compared using stratified Cox regression. Elderly transplant recipients (KTRs) (n = 465) were matched to waitlisted pairs. Transplant group mortality initially exceeded dialysis due to excess infection-related deaths (1.9 transplant versus 0.3 dialysis/100 patient-years, P = .03). Beyond month 9, a progressive survival benefit in favor of transplantation was apparent. Over a median follow-up of 1.7 years, mortality was 38% lower for KTRs (95% confidence interval 0.41-0.94, P = .02), and 5-year survival was 80% KTRs vs 53% dialysis (P < .001). Recipients of living and standard criteria donor kidneys acquired immediate survival advantage compared with dialysis, while recipients of expanded criteria donor's kidneys experienced elevated risk of death for the first 17 months. Compared with remaining on dialysis, elderly KTRs incur an increased risk of early posttransplant mortality but thereafter may anticipate progressively superior survival rates.

22 May 2025 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
GPGriffith Perkins
Griffith Perkins
MTMatthew J. Tunbridge
Matthew J. Tunbridge
CCCheng Sheng Chai
Cheng Sheng Chai
CHChris Hope
Chris Hope
AYArthur Eng Lip Yeow
Arthur Eng Lip Yeow
PCP. Toby Coates
P. Toby Coates
Key Points: Mechanistic target of rapamycin (mTOR) inhibitor–based immunosuppression was associated with an improved T-cell response to vaccination in kidney transplant recipients. Mice treated with an mTOR inhibitor exhibited improved T-cell responses to booster vaccination. Switching low and nonresponder kidney transplant recipients to an mTOR inhibitor did not improve T-cell response to a booster vaccination. Background: Failure to develop protective immunity in response to vaccination is common among kidney transplant recipients, rendering them susceptible to severe infection. Novel strategies are required. Here, we investigated the potential of mechanistic target of rapamycin (mTOR) inhibitors to improve vaccine responses. Methods: Humoral and cellular responses to primary coronavirus disease 2019 (COVID-19) vaccination (ChAdOx1 or BNT162b2) were assessed for kidney transplant recipients receiving mTOR inhibitor–based (mTOR inhibitor, mycophenolate, prednisolone, n =15) and standard-of-care (tacrolimus, mycophenolate, prednisolone, n =40) immunosuppression, and healthy cohabitants ( n =71), in a prospective observational study. Findings were validated and mechanisms explored in mice. Low/nonresponding kidney transplant recipients receiving standard-of-care immunosuppression ( N =54) were then randomized 1:1 to switch from mycophenolate to sirolimus or remain on standard of care for 4 weeks before receiving COVID-19 booster vaccination. Augmentation of immunity to COVID-19 was assessed as the primary outcome measure. Results: A 12-fold greater IFN γ T-cell response to primary vaccination was observed in kidney transplant recipients receiving mTOR inhibitor–based versus standard-of-care immunosuppression (520 versus 43 spot-forming units/10 6 cells, P < 0.001). A greater frequency of functional memory T cells in the mTOR inhibitor group was observed for both the CD4 + (0.20% versus 0.05%, P < 0.001) and CD8 + (0.35% versus 0.07%, P = 0.006) compartments by flow cytometry, and kidney transplant recipients receiving mTOR inhibitor–based immunosuppression produced greater frequencies of severe acute respiratory syndrome coronavirus 2–specific CD4 + T cells than healthy cohabitants (1.17% versus 0.48%, P = 0.03). In mice, sirolimus treatment enhanced both recall and de novo T-cell responses to homologous and Omicron-specific booster vaccines. Switch from mycophenolate to sirolimus was well tolerated; however, no significant difference was observed in the proportion of kidney transplant recipients in the intervention and control arms that achieved protective virus neutralization (10/25 [40%] versus 9/21 [43%], respectively, P = 0.85) nor in T-cell response to vaccination ( P = 0.89). Conclusions: mTOR inhibition was associated with improved T-cell memory formation in kidney transplant recipients; however, this effect was not reproduced by a short-term mycophenolate to sirolimus switch strategy. Clinical Trial registry name and registration number: Australian New Zealand Clinical Trials Registry, ACTRN12621001412820.

25 February 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
BSBree Shi
Bree Shi
JBJonathan M. Bleasel
Jonathan M. Bleasel
TYTracey Ying
Tracey Ying
SCSteve J Chadban
Steve J Chadban
Key Points: Many kidney transplant noninferiority trials used unjustified or overly generous margins, risking adoption of inferior therapies. Inadequate analyses, poor missing data handling, and weak Consolidated Standards of Reporting Trials (CONSORT) adherence limit trial interpretation. Stronger noninferiority trial design and reporting are needed to improve evidence quality in kidney transplantation. Background: Noninferiority trials are essential in kidney transplantation, where established standard-of-care treatments make placebo-controlled designs infeasible, and their use is increasing. We aimed to assess the design and reporting quality of noninferiority trials in kidney transplantation, specifically assessing adherence to existing guidelines. Methods: We searched medical literature analysis and retrieval system online, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled noninferiority trials in kidney transplantation published up to February 2025. Two investigators reviewed and extracted data. Study quality was assessed regarding design and reporting quality using key noninferiority design criteria and the Consolidated Standards of Reporting Trials 2012 extension, respectively. Results: We identified 43 unique trials: 36 (84%) compared a novel immunosuppressive regimen to standard of care and 26 (60%) were industry sponsored. The noninferiority margin (the worst-case loss in efficacy considered clinically acceptable) was not justified in 28 (65%) studies and poorly justified in seven (16%). Of 32 studies with a categorical primary outcome, 30 (94%) assessed absolute risk reduction rather than relative risk. Most studies had high withdrawal and dropout rates, yet 33 (77%) did not specify methods for handling missing data. Intention-to-treat analysis alone was used to determine primary efficacy in 24 (56%) studies. Twelve studies (28%) provided an incorrect conclusion, most claiming equivalence when noninferiority had not been adequately demonstrated. Both design and reporting quality have improved over time ( P = 0.02, P = 0.002, respectively). No association was evident between design or reporting quality and journal impact factor or sponsor type. Conclusions: We found major deficiencies in the design, conduct, and reporting of noninferiority trials in kidney transplantation.